Clinical Study of Titration Treatment for Moderate Cancer Pain with Oxycodone Hydrochloride Sustained-release Tablets

Jian-guo ZHAO,Jian-fang WANG,Dong-ping WU,Jian-ping XIONG

DOI: https://doi.org/10.6039/j.issn.1001-0408.2014.46.18

2014-01-01

Abstract:OBJECTIVE:To study therapeutic efficacy and adverse reactions advantage of titration and maintenance therapy of Oxycodone hydrochloride sustained-release tablets for moderate cancer pain. METHODS:70 moderate cancer pain patients without opioids history were collected and divided into 2 groups according to the proportion of 1∶1. Group A received Oxycodone hydrochloride sustained-release tablets with initial dose of 10 mg,and group B received Morphine immediate-release tablets 5-10 mg for titration. Patients who achieved partial remission or complete remission were respectively treated with Oxycodone hydrochloride sustained-release tablets and Morphine sulfate sustained-release tablets as maintenance therapy. The rate of pain relief and the incidence of ADR were compared between 2 groups. RESULTS:1 h after medication,the effective rate was 62.9% in group A and 37.1% in group B,there was significant difference between 2 groups(P0.05);12 h after medication,the effective rate was 80.0% in group A and 57.1% in group B,there was also significant difference between 2 groups(P0.05);24 h,48 h and 72 h after medication,there was no statistical significance between 2 groups(P0.05). The main ADR were constipation,dizziness,nausea,vomiting,lethargy and anorexia. The incidence of constipation and nausea in group A was significantly lower than in group B,there was significant difference between 2 groups(P0.05);there was no statistical significance in the incidence of other ADR(P0.05). CONCLUSIONS:Titration therapy of Oxycodone hydrochloride sustained-release tablets has rapid onset for moderate cancer pain,and demonstrate low incidence of constipation and nausea;therefore,it is the first choice for moderate cancer pain.